TherapeuticsMD, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
TherapeuticsMD, Inc. (TXMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.84 per share for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2019-11-08
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $3.35, a 7.72% increase year-over-year.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-03-31 was $3.11, a 21.46% decline year-over-year.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-03-31 was $3.96, a 19.35% decline year-over-year.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2016-03-31 was $4.91.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $3.94, a 11.46% decline from fiscal 2015.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was $4.45.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2012 was $1.16, a 625.00% increase from fiscal 2011.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2011 was $0.16.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2019-09-30 | $1.84 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $2.57 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $3.35 10-Q · filed 2019-05-08 | |||
| 2018-09-30 | $3.27 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | $3.15 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | $3.11 10-Q · filed 2019-05-08 | |||
| 2017-09-30 | $3.82 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $3.82 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $3.96 10-Q · filed 2017-05-03 | |||
| 2016-12-31 | $3.94 10-K · filed 2017-02-28 | |||
| 2016-09-30 | $4.70 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $5.08 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | $4.91 10-Q · filed 2017-05-03 | |||
| 2015-12-31 | $4.45 10-K · filed 2016-02-26 | |||
| 2013-03-31 | $0.87 10-Q · filed 2013-05-10 | |||
| 2012-12-31 | $1.16 10-K · filed 2013-03-12 | |||
| 2011-12-31 | $0.16 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |